Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancera management?

Expert Review of Molecular Diagnostics

Volumn 10, Issue 3, 2010, Pages 247-250

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CHOLESTEROL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB;

BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CANCER THERAPY; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; COLORECTAL CANCER; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONSENSUS; EDITORIAL; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL RESEARCH; MEDICINE; MICROMETASTASIS; MISMATCH REPAIR; PATIENT CARE; PERSONALIZED MEDICINE; PRIMARY PREVENTION; PUBLIC HEALTH; STOMACH CANCER;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; HUMANS; INDIVIDUALIZED MEDICINE; MASS SCREENING; NEOPLASMS;

EID: 77950607162     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.10     Document Type: Editorial

References (34)

1. Mushlin AI, Ghomrawi H. Health care reform and the need for comparative-effectiveness research. N. Engl. J. Med. 362(3), e6 (2010).
2. Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N. Engl. J. Med. 360(19), 1925-1927 (2009).
3. Valid concerns. Nature 463(7280), 401-402 (2010).
4. Lin K, Lipsitz R, Miller T, Janakiraman S; US Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med. 149(3), 192-199 (2008).
5. AJCC Cancer Staging Manual (7th Edition). Edge SE, Byrd DR, Carducci MA, Compton CA (Eds). Springer, NY, USA (2009).
6. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994). (Pubitemid 24345325)
7. Wooster R Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
8. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76(1), 1-18 (2009).
9. Guilford P, Hopkins J, Harraway J et al. E-cadherin germline mutations in familial gastric cancer. Nature 392(6674), 402-405 (1998). (Pubitemid 28168738)
10. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
11. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360(14), 1408-1417 (2009).
12. Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 458(7236), 290-292 (2009).
13. Roukos DH. Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev. Anticancer Ther. 9(10), 1413-1416 (2009).
14. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005).
15. Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev. Anticancer Ther. 10(2), 123-128 (2010).
16. Roukos DH. Mea kulpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn. 9(3), 217-221 (2009).
17. de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med. 361(7), 653-663 (2009).
18. Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med. 361, 1994-1995 (2009).
19. Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007).
20. Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2006).
21. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
22. Pleasance ED, Stephens PJ, O'Meara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184-190 (2010).
23. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196 (2010).
24. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461(7265), 809-813 (2009).
25. Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 462(7276), 1005-1010 (2009).
26. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
27. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med. 360(8), 790-800 (2009).
28. Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol. 27(8), 1337-1338 (2009).
29. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer 2(5), 331-341 (2002).
30. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
31. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010).
32. Deisboeck TS. Personalizing medicine: a systems biology perspective. Mol. Syst. Biol. 5, 249 (2009).
33. Goldstein DB. 2020 visions. Personalized medicine. Nature 463, 27 (2010).
34. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).